Add Company
Join Now

Tolerx Revenue and Competitors

License our Company Data API

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tolerx's estimated annual revenue is currently $1.7M per year.(i)
  • Tolerx's estimated revenue per employee is $155,000

Employee Data

  • Tolerx has 11 Employees.(i)
  • Tolerx grew their employee count by 0% last year.

Tolerx's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Tolerx?

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candidates to treat type 1 diabetes, other autoimmune diseases, and cancer by normalizing immune responses. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunotherapy in Phase 3 development for type 1 diabetes, for which Tolerx is partnered with GlaxoSmithKline. A second clinical product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for cancer. TRX1, a third immunotherapy candidate, is an anti-CD4 antibody that has been clinically evaluated for the treatment of aberrant or untoward immune responses. The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and are being evaluated for potential benefit in the treatment of cancer and chronic viral infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$1.7M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M11N/AN/A
#2
$1.8M11N/AN/A
#3
$3.5M11-31%$116.2M
#4
$2.9M110%N/A
#5
$0.9M11-45%$107M